TLC Announces Full Enrollment in Part 1 of Phase II Trial of TLC590 for Postsurgical Pain Management following Bunionectomy
April 08, 2019 05:00 ET
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, April 08, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
TLC Reports Fourth Quarter and Full Year 2018 Financial Results and Business Update
April 01, 2019 05:00 ET
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, April 01, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
TLC to Present High-Scoring Scientific Abstracts on Acute Pain through Moderated Sessions at ASRA Spring 2019
March 25, 2019 05:00 ET
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPAI, Taiwan, March 25, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
TLC Announces First Patient Dosed in Phase II Trial of TLC590 for Postsurgical Pain Management following Bunionectomy
March 18, 2019 05:00 ET
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 18, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
TLC Reports Positive Top-Line Results from Phase I/II Clinical Trial of TLC590 for Postsurgical Pain
March 11, 2019 06:27 ET
|
Taiwan Liposome Company, Ltd.
TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
TLC and 3SBio Form Exclusive Partnership to Commercialize Two NanoX™ Products in Mainland China
March 03, 2019 21:57 ET
|
Taiwan Liposome Company, Ltd.
SOUTH SAN FRANCISCO, Calif., TAIWAN, SHEN YANG, China and HONG KONG, March 04, 2019 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (“TLC”)(Nasdaq: TLC, TWO: 4152), a clinical-stage specialty...
TLC Appoints George Spencer-Green, MD, MS, as Chief Medical Officer
January 25, 2019 03:53 ET
|
Taiwan Liposome Company, Ltd.
TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., Jan. 25, 2019 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated...
EMA Grants Orphan Drug Designation to TLC178 for the Treatment of Soft Tissue Sarcoma
January 22, 2019 06:00 ET
|
Taiwan Liposome Company, Ltd.
TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated...
TLC Announces Phase I/II Full Enrollment in Hernia Repair Surgery and Phase II Initiation in Bunionectomy of TLC590 for Postsurgical Pain
December 18, 2018 05:30 ET
|
Taiwan Liposome Company, Ltd.
TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated...
TLC to Attend Goldman Sachs Asia Pacific Healthcare Forum 2018
November 25, 2018 06:00 ET
|
Taiwan Liposome Company, Ltd.
TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., Nov. 25, 2018 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated...